Literature DB >> 9329528

Generalisation from phase III clinical trials: survival, quality of life, and health economics.

P M Fayers1, D J Hand.   

Abstract

Keywords:  Biomedical and Behavioral Research

Mesh：

Year:  1997        PMID： 9329528     DOI： 10.1016/s0140-6736(97)03053-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  15 in total

1.  Importance of health economics must be recognised when trials are designed.

Authors:  A Haycox; A Bagust; T Walley
Journal:  BMJ       Date:  1999-06-19

Review 2.  How should cost data in pragmatic randomised trials be analysed?

Authors:  S G Thompson; J A Barber
Journal:  BMJ       Date:  2000-04-29

Review 3.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  Economic analysis of randomized, controlled trials.

Authors:  G H Lyman
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

5.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  J Soto
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

6.  The problem of protocol driven costs in pharmacoeconomic analysis.

Authors:  D Coyle; K M Lee
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

7.  CAM before the storm: authors' reply.

Authors:  Trevor D Thompson; Gene Feder
Journal:  BMJ       Date:  2005-11-19

8.  Incorporating adherence into health economic modelling of osteoporosis.

Authors:  O Ström; F Borgström; J A Kanis; B Jönsson
Journal:  Osteoporos Int       Date:  2008-06-03       Impact factor: 4.507

Review 9.  Analysis and interpretation of cost data in randomised controlled trials: review of published studies.

Authors:  J A Barber; S G Thompson
Journal:  BMJ       Date:  1998-10-31

10.  From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.

Authors:  Samuel Limat; Marie-Christine Woronoff-Lemsi; Céline Menat; Anne Madroszyk-Flandin; Yacine Merrouche
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.